Current research in side effects of high-dose chemotherapy

Odaimi, 1987, High-dose chemotherapy: Concepts and strategies, Am J Clin Oncol, 10, 123, 10.1097/00000421-198704000-00045 DeVita, 1989, Principles of chemotherapy, 276 Hryniuk, 1987, The importance of dose intensity in chemotherapy for metastatic breast cancer, J Clin Oncol, 5, 756 Hryniuk, 1987, Application of dose intensification to problems in chemotherapy of breast and colorectal cancer, 14, 3 Levin, 1987, Dose intensity analysis of cyclophosphamide regimens in ovarian cancer, J Clin Oncol, 47, 5810 McMaster, 1991, Effective treatment of small-noncleaved-cell lymphoma with high intensity, brief duration chemotherapy, J Clin Oncol, 9, 941, 10.1200/JCO.1991.9.6.941 Gorin, 1991, Autologous bone marrow transplantation in hematological malignancies, Am J Clin Oncol, 14, S5, 10.1097/00000421-199112001-00003 Schulz, 1991, New therapeutic modalities for the clinical use of rhGM-CSF in patients with malignancy, Am J Clin Oncol, 14, S10, 10.1097/00000421-199112001-00005 Wang, 1952, A new concept of organization of the central emetic mechanism: Recent studies on the sites of action of apomorphine, copper sulfate, and cardiac glycosides, Gastroenterology, 22, 1, 10.1016/S0016-5085(19)36357-7 Borison, 1986, Anatomy and physiology of the chemoreceptor zone and area post rema, 10 Borison, 1983, Neuropharmacology of chemotherapy induced emesis, Drugs, 25, 8, 10.2165/00003495-198300251-00003 Gralla, 1989, Adverse effects of treatment, 2135 Wickham, 1989, Managing chemotherapy related nausea and vomiting: The state of the art, 16, 563 Gralla, 1981, Antiemetic efficacy of high dose metoclopramide: Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting, N Engl J Med, 305, 905, 10.1056/NEJM198110153051601 Gralla, 1983, Metoclopramide: A review of antiemetic trials, Drugs, 25, 63, 10.2165/00003495-198300251-00007 Kris, 1987, Antiemetic control and prevention of side effects of anticancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone: A double blind randomized trial, Cancer, 60, 2816, 10.1002/1097-0142(19871201)60:11<2816::AID-CNCR2820601137>3.0.CO;2-7 Costall, 1987, GR 38032F: A potent and novel inhibitor of cisplatin-induced emesis in the ferret, Br J Pharmacol, 90, 90 Gannon, 1990, Focus on ondansetron: An antiemetic with a unique mechanism of action, Hosp Formul, 25, 1209 Cubbeddu, 1990, Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting, N Engl J Med, 322, 810, 10.1056/NEJM199003223221204 Einhorn, 1990, Ondansetron: A new antiemetic for patients receiving cisplatin chemotherapy, J Clin Oncol, 8, 731, 10.1200/JCO.1990.8.4.731 Chaffee, 1991, Ondansetron—the first of a new class of antiemetic agents, Clin Pharmacol, 10, 430 Marty, 1990, Comparison of the 5-hydroxytryptamine (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis, N Engl J Med, 322, 816, 10.1056/NEJM199003223221205 Smith, 1991, A double randomized crossover trial comparing ondansetron and dexamethasone with ondansetron and placebo as antiemetic prophylaxis against high dose cisplatin chemotherapy, 10, 321 Kaasa, 1990, A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy induced nausea and vomiting: A randomized, doubleblind study, Eur J Cancer, 26, 311, 10.1016/0277-5379(90)90227-K Hainsworth, 1991, A singleblind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy, J Clin Oncol, 9, 721, 10.1200/JCO.1991.9.5.721 Bonneterre, 1990, A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubucin chemotherapy, J Clin Oncol, 8, 1063, 10.1200/JCO.1990.8.6.1063 Fraschini, 1991, Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy, J Clin Oncol, 9, 1268, 10.1200/JCO.1991.9.7.1268 Smaldone, 1991, Randomized double-blind cross over comparison of batanopride (BMY-25801) and metoclopramide (MTC) in patients receiving cisplatin-based chemotherapy (CT), 10, 342 Smaldone, 1991, Antiemetic activity of the batanopride (BMY-25801) in patients receiving cisplatin: A randomized double-blind parallel comparison of two doses, 10, 326 Aapro, 1991, Granisetron vs. metoclopramide plus dexamethasone (MET/DEX) in patients (PTS) receiving five-day chemotherapy, 10, 331 Kaplan, 1991, Use of granisetron (BRL-43694A) to prevent platinol (CDDP)-induced nausea and vomiting, 10, 339 Warr, 1991, Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy induced emesis, J Natl Cancer Inst, 83, 1169, 10.1093/jnci/83.16.1169 Baltzer, 1991, Dose ranging antiemetic study of the serotonin antagonists (RG 12915), 10, 341 Kirchner, 1991, Safety and antiemetic effect of MDL 73-147EF, a new 5-HT3 antagonist in 41 patients requiring intravenous cytotoxic chemotherapy, 10, 337 Cotanch, 1987, Progressive muscle relaxation as antiemetic therapy for cancer patients, 14, 33 Scott, 1986, Comparative trial of clinical relaxation and an antiemetic drug regimen in reducing chemotherapy-induced nausea and vomiting, Cancer Nurs, 9, 178, 10.1097/00002820-198608000-00005 Frank, 1985, The effects of music therapy and guided visual imagery on chemotherapy-induced nausea and vomiting, 12, 47 Cotanch, 1985, Self-hypnosis as antiemetic therapy in children receiving chemotherapy, 12, 41 Winningham, 1988, The effect of aerobic exercise on patient reports of nausea, 15, 447 McHugh, 1982, Preparatory information: What helps and why, Am J Nurs, 82, 780 Iwamoto, 1991, Alterations in oral status, 742 Lockhart, 1990, Oral complications following neoadjuvant chemotherapy in patients with head and neck cancer, NCI Monogr, 9, 99 Sonis, 1990, An animal model for mucositis induced by cancer chemotherapy, Oral Surg Oral Med Oral Pathol, 69, 427, 10.1016/0030-4220(90)90376-4 Sonis, 1983, Epidemiology, frequency distribution, mechanisms, and histopathology, 1 Dreizen, 1990, Description and incidence of oral complications, NCI Monogr, 9, 11 Greenberg, 1990, Prechemotherapy dental treatment to prevent bacteria, NCI Monogr, 9, 49 Gabrilove, 1988, Effect of G-CSF on neutropenia and associated morbidity due to chemotherapy for transitional cell cancer of the urothelium, N Engl J Med, 318, 1414, 10.1056/NEJM198806023182202 Beck, 1979, Impact of a systematic oral care protocol in stomatitis after chemotherapy, Cancer Nurs, 2, 185, 10.1097/00002820-197906000-00002 Miaskowski, 1990, Management of mucositis during therapy, NCI Monogr, 9, 95 Bavier, 1990, Nursing management of acute oral complications of cancer, NCI Monogr, 9, 123 Lydon, 1990, Integumentary and mucous membrane alterations, 594 Ferrett, 1990, Oral antimicrobial agents—chlorhexidine, NCI Monogr, 9, 51 Redding SW: Role of herpes simplex virus reactivation in chemotherapy-induced oral mucositis. NCI Monogr 9:103–105 Saral, 1990, Management of acute viral infections, NCI Monogr, 9, 107 Chabner, 1989, Clinical pharmacology of cancer chemotherapy, 349 Mahood, 1991, Inhibition of fluorouracil-induced stomatitis by oral cryotherapy, J Clin Oncol, 9, 449, 10.1200/JCO.1991.9.3.449 Grant, 1991, Alterations in nutrition, 717 Field, 1989, Intestinal electrolyte transport and diarrheal disease (First of two parts), N Engl J Med, 321, 800, 10.1056/NEJM198909213211206 Field, 1989, Intestinal electrolyte transport and diarrheal disease (Second of two parts), N Engl J Med, 321, 879, 10.1056/NEJM198909283211307 Katz, 1989, Octreotide, a new somatostatin analogue, Clin Pharm, 8, 255 Gullatte, 1990, Advances in antineoplastic therapy, 17, 867 Katz, 1988, Treatment of severe diarrhea with octreotide in a patient with AIDS, Drug Intell Clin Pharm, 22, 135 Rosenburg, 1988, Octreotide: A synthetic analog of somatostatin, Drug Intell Clin Pharm, 22, 748, 10.1177/106002808802201001 Kennedy, 1990, Sandostatin (s) therapy for chemotherapy (CT) and radiotherapy (RT) related diarrhea, 9, 324 Tenny, 1991, Octreotide for transplant-related diarrhea, 10, 329 Vanachek, 1991, Gastrointestinal complications following bone marrow transplantation, 206 Ely, 1991, Use of a somatostatin analogue, octreotide acetate, in the management of acute gastrointestional graft-versus-host-disease, Am J Med, 90, 707, 10.1016/S0002-9343(05)80059-2 Bonnadonna, 1969, Cardiotoxicity of daunorubicin, Lancet, 1, 837, 10.1016/S0140-6736(69)92093-5 Bristow, 1978, Clinical spectrum of anthracycline cardiotoxicity, Cancer Treat Rep, 62, 873 VonHoff, 1979, Risk factors for doxorubicin induced congestive heart failure, Ann Intern Med, 91, 701 Torti, 1989, Cardiac toxicity, 2153 Steinherz, 1991, Delayed anthracycline cardiac toxicities, PPO Updates, 4, 1 1989 Gottdiener, 1981, Cardiotoxicity associated with high dose cyclophosphamide therapy, Arch Intern Med, 141, 758, 10.1001/archinte.1981.00340060066015 Kupari, 1990, Cardiac involvement in bone marrow transplantation: Serial changes in left ventricular size, mass, and performance, J Intern Med, 227, 259, 10.1111/j.1365-2796.1990.tb00155.x Wilke, 1991, Pulmonary and cardiac complications of bone marrow transplantation, 182 Braverman, 1991, Cyclophosphamide cardiotoxicity in bone marrow transplantation: Aprospective evaluation of new dosing regimens, J Clin Oncol, 9, 1215, 10.1200/JCO.1991.9.7.1215 Dent, 1975, 5-fluorouracil and angina, Lancet, 1, 347, 10.1016/S0140-6736(75)91270-2 Burger, 1987, 5-fluorouracil-induced coronary vasospasm, Am Heart J, 114, 433, 10.1016/0002-8703(87)90517-5 Stevenson, 1977, Cardiotoxicity of 5-fluorouracil, Lancet, 1, 406, 10.1016/S0140-6736(77)90339-7 Kleiman, 1987, Prinzmetal's angina during 5-fluorouracil chemotherapy, Am J Med, 82, 566, 10.1016/0002-9343(87)90465-7 Oleksowicz, 1988, Prophylaxis of 5-fluorouracil induced coronary vasospasm with calcium channel blockers, Am J Med, 85, 750, 10.1016/S0002-9343(88)80268-7 Chabner, 1991, Taxol, PPO Updates, 9, 1 Rowinsky, 1989, Phase I and pharmacodynamic study of taxol in acute adult leukemias, Cancer Res, 41, 4640 Rowinsky, 1991, Sequences of taxol and cisplatin: A phase I and pharmacologic study, J Clin Oncol, 9, 1692, 10.1200/JCO.1991.9.9.1692 Shenkenber, 1986, Mitoxantrone: A new anticancer drug with significant clinical activity, Ann Intern Med, 105, 67, 10.7326/0003-4819-105-1-67 Vorobiof, 1983, Amsacrine cardiotoxicity: Assessment of ventricular function by radionuclide angiography, Cancer Treat Rep, 67, 1115 Dorr, 1991, Chemoprotectants for cancer chemotherapy, 18, 48 Herman, 1982, Biological properties of ICF-159 and related bis (dioxopeperazine) compounds, Adv Pharmacol Chemother, 19, 249, 10.1016/S1054-3589(08)60025-3 Hasinoff, 1989, The interaction of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane—its hydrolysis product (ICRF 198); and other chelating agents with the Fe (III) and Cu (II) complexes of Adriamycin, Agents Actions, 26, 378, 10.1007/BF01967305 Speyer, 1988, Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer, N Engl J Med, 319, 745, 10.1056/NEJM198809223191203 Ballard, 1991, Renal and hepatic complications, 240 Higgs, 1989, Ifosfamide: A clinicalreview, 5, 70 Price, 1990, Fatal hemorrhagic cystitis induced by pelvic irradiation and cyclophosphamide therapy, Minn Med, 73, 39 Chabner, 1989, Clinical pharmacology of cancer chemotherapy, 349 Lydon, 1986, Nephrotoxicity of cancer treatment, 13, 68 Gandara, 1991, Cisplatin chemoprotection and rescue: Pharmacologic modulation of toxicity, 18, 49 Mollman, 1988, Cisplatin neuropathy: Risk factors, prognosis, and protection by WR-2721, Cancer, 61, 2192, 10.1002/1097-0142(19880601)61:11<2192::AID-CNCR2820611110>3.0.CO;2-A Kemp, 1990, The role of WR-2721 in the reduction of combined cisplatin and cyclophosphamide toxicity, 9, 67 Glover, 1986, Phase I/II trials of WR-2721 and cisplatin, Int J Radiat Oncol Biol Phys, 12, 1509, 10.1016/0360-3016(86)90205-1 DeGregorio, 1989, High-dose cisplatin with diethyldithiocarbamate (DDTC) rescue therapy: Preliminary pharmacologie observations, Cancer Chemother Pharmacol, 23, 276, 10.1007/BF00292403 Gandara, 1989, Phase I trial of high dose cisplatin plus diethyldithiocarbamate rescue: Toxicity profile compared to patients receiving high dose cisplatin alone, 30, 60 Locherer, 1991, Ifosfamide extrapyramidal neurotoxicity, Cancer, 68, 72, 10.1002/1097-0142(19910701)68:1<72::AID-CNCR2820680114>3.0.CO;2-# Litterst, 1981, Alterations in the toxicity of cis-dichlorodiammineplatinum-II and in tissue localization of platinum is a function of NACl concentration in the vehicle of administration, Toxicol Appl Pharmacol, 61, 99, 10.1016/0041-008X(81)90011-9 Legha, 1985, High dose cisplatin administration without hypertonic saline: Observation of disabling neurotoxicity, J Clin Oncol, 3, 1371, 10.1200/JCO.1985.3.10.1373 Thigpen, 1991, Phase II trial of taxol as a second-line therapy for ovarian cancer Jackson, 1988, Amelioration of vincristine toxicity by glutamic acid, Am J Med, 84, 1016, 10.1016/0002-9343(88)90306-3 Goren, 1986, Dechloroethylation of ifosfamide and neurotoxicity, Lancet, 2, 1219, 10.1016/S0140-6736(86)92227-0 Garosy, 1989, Ifosfamide—pharmacology overview, 16, 2